Missed the webinar? Here are Investing.com’s top 10 stock picks for 2026
Investing.com -- Stereotaxis Inc. (NYSE:STXS) shares fell 7% in after-hours trading Tuesday after the surgical robotics company reported third-quarter revenue that missed analyst expectations and provided weaker-than-expected guidance for the current quarter.
The pioneer in minimally invasive endovascular intervention reported third-quarter revenue of $7.46 million, falling short of the $8.38 million consensus estimate. The company posted an adjusted loss of $0.07 per share, slightly worse than analysts’ expectations for a loss of $0.06 per share. Revenue increased from the prior year when the company reported $9.2 million, driven by system revenue of $1.9 million and recurring revenue of $5.6 million.
Stereotaxis provided fourth-quarter revenue guidance exceeding $9 million, below the consensus estimate of $9.9 million, contributing to the negative market reaction.
"We continue to focus on driving commercial progress while advancing a robust portfolio of technologies through regulatory and development milestones," said David Fischel, Chairman and CEO. "This is an exciting milestone-rich period in which we are demonstrating the tangible reality and initial commercial impact of our comprehensive innovation strategy."
The company reported gross margin of 55% for the quarter, with recurring revenue gross margin at 67% and system gross margin at 19%. Operating expenses totaled $10.7 million, including $4.1 million in non-cash charges.
Stereotaxis secured two Genesis robotic system orders from European hospitals since its last quarterly update. The company also highlighted recent regulatory achievements, including FDA clearance for the GenesisX robotic system and European CE Mark receipt for its Synchrony digital cath lab technology.
As of September 30, 2025, the company had $10.5 million in cash and no debt. Including an upcoming $4 million from a previously announced financing, Stereotaxis would have $14.5 million in cash.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.